Skip to main content
. 2023 Feb 22;54:251–269. doi: 10.1016/j.jare.2023.02.004

Table 2.

Cytotoxicity in HEK293 cells (CC50 in µg/mL) and haemolytic activity in RBC (HC10 in µg/mL) of the most promising phytochemical-based TPP+ conjugates.

Compound HEK293 (CC50)a RBC (HC10) b Compound HEK293 (CC50)a RBC (HC10) b
graphic file with name fx1.gif 9.07 >32 graphic file with name fx2.gif >32 >32
graphic file with name fx3.gif >32 >32 graphic file with name fx4.gif >32 >32
graphic file with name fx5.gif 31.2 >32 graphic file with name fx6.gif 10.7 11.9
graphic file with name fx7.gif >32 >32 graphic file with name fx8.gif >32 6.0
graphic file with name fx9.gif >32 >32 graphic file with name fx10.gif >32 >32
graphic file with name fx11.gif >32 >32 graphic file with name fx12.gif 22.4 >32
graphic file with name fx13.gif >32 >32 graphic file with name fx14.gif >32 11.8
Tamoxifen 9 __
Mellitin __ 2.7
a

CC50: concentration at 50 % cytotoxicity in human embryonic kidney (HEK-293) cells. bHC10: concentration at 10% haemolytic activity in human red blood (RBC) cells.